Between Jan News Today

1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT) is a

1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT)

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy is a

1. Patients in the pembrolizumab plus chemotherapy group reported a significantly greater overall survival compared to those in the chemotherapy alone group (17.3 months vs. 16.1 months). 2. Grade 5 adverse events were comparable in both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Pleural mesothelioma often presents at an advanced stage, and platinum–pemetrexed chemotherapy

1. Neonatal morbidity rate was comparable between the continuous oxytocin and discontinuous oxytocin groups. 2. There was no significant difference in adverse events between both groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Oxytocin is known for reducing labour duration but may pose risks for neonatal morbidity. In the multicenter STOPOXY trial, participants receiving oxytocin

1. HbA1c reduction was dose-dependent in the semaglutide group with the greatest change among patients on semaglutide 50 mg. 2. Higher doses of semaglutide were associated with more gastrointestinal symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Maintaining glycemic control is an important goal for patients with type 2 diabetes. Currently, GLP-1 agonists, such as

1. Complete response or remission was reported in 18% of patients who received a single liso-cel infusion. 2. Nearly 10% of fatalities were thought to be due to liso-cel related complications. Evidence Rating Level: 1 (Excellent) Study Rundown: There exist limited options for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic

1. Mean MADRS change at week 6 was -8.2 in the active tDCS group versus -8.0 in the sham tDCS group. 2. There were significantly more adverse events in the active tDCS group. Evidence Rating Level: 1 (Excellent) Study Rundown: Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive disorder (MDD),

1. Mean MADRS change at week 6 was -8.2 in the active tDCS group versus -8.0 in the sham tDCS group. 2. There were significantly more adverse events in the active tDCS group. Evidence Rating Level: 1 (Excellent) Study Rundown: Transcranial direct current stimulation (tDCS) has been proposed as a feasible treatment for major depressive

1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no treatment-related fatalities among patients in the talazoparib group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the second most common malignancy among men. Despite existing therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a